North America Human Vaccine Adjuvants Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2030 - Regional Analysis - by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)

No. of Pages: 109    |    Report Code: BMIRE00030498    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Human Vaccine Adjuvants Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Human Vaccine Adjuvants Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Human Vaccine Adjuvants Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Growing focus on immunization is propelling the vaccine production
5.2 Market Opportunities
  • 5.2.1 Growing Pharmaceutical Industry Create Lucrative Growth Opportunities
5.3 Future Trends
  • 5.3.1 Increasing burden of chronic diseases has led to a growing demand for vaccines
5.4 Impact of Drivers and Restraints

6. North America Human Vaccine Adjuvants Market Regional Analysis

6.1 North America Human Vaccine Adjuvants Market Overview
6.2 North America Human Vaccine Adjuvants Market Revenue 2020-2030 (US$ Million)
6.3 North America Human Vaccine Adjuvants Market Forecast Analysis

7. North America Human Vaccine Adjuvants Market Analysis – by Type

7.1 Particulate Adjuvant
  • 7.1.1 Overview
  • 7.1.2 Particulate Adjuvant: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Emulsion Adjuvant
  • 7.2.1 Overview
  • 7.2.2 Emulsion Adjuvant: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Combination Adjuvant
  • 7.3.1 Overview
  • 7.3.2 Combination Adjuvant: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Human Vaccine Adjuvants Market Analysis – by Application

8.1 Influenza
  • 8.1.1 Overview
  • 8.1.2 Influenza: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Hepatitis
  • 8.2.1 Overview
  • 8.2.2 Hepatitis: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Human papilloma virus
  • 8.3.1 Overview
  • 8.3.2 Human papilloma virus: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

9. North America Human Vaccine Adjuvants Market Analysis – by End User

9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Overview
  • 9.1.2 Human papilloma virus: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2 CMOs and CROs
  • 9.2.1 Overview
  • 9.2.2 Human papilloma virus: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10. North America Human Vaccine Adjuvants Market – North America Analysis

10.1 North America
  • 10.1.1 North America Human Vaccine Adjuvants Market Breakdown, by Key Country, 2023 and 2030 (%)
  • 10.1.1.1 North America Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.1.1 US: North America Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.1.1.1.2 US: North America Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.1.1.1.3 US: North America Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.1.1.2 Canada: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.2.1 Canada: North America Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.1.1.2.2 Canada: North America Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.1.1.2.3 Canada: North America Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.1.1.3 Mexico : North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.1.1.3.2 Mexico : North America Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.1.1.3.3 Mexico : North America Human Vaccine Adjuvants Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Human Vaccine Adjuvants Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Creative Biolabs Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Croda International Plc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 CSL Ltd
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Dynavax Technologies Corp
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Hawaii Biotech Inc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Novartis AG
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Novavax Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Phibro Animal Health Corp
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Seppic SA
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 SPI Pharma Inc
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

1. Creative Biolabs Inc 
2. Croda International Plc 
3. CSL Ltd 
4. Dynavax Technologies Corp 
5. Hawaii Biotech Inc 
6. Novartis AG 
7. Novavax Inc 
8. Phibro Animal Health Corp 
9. Seppic SA 
10. SPI Pharma Inc 

north-america-human-vaccine-adjuvants-market